Simple clinical predictors may obviate urgent endoscopy in selected patients with nonvariceal upper gastrointestinal tract bleeding

被引:76
作者
Romagnuolo, Joseph
Barkun, Alan N.
Enns, Robert
Armstrong, David
Gregor, Jamie
机构
[1] Med Univ S Carolina, Dept Med & Biometry, Charleston, SC 29425 USA
[2] Med Univ S Carolina, Dept Bioinformat & Epidemiol, Charleston, SC 29425 USA
[3] McGill Univ, Dept Med, Montreal, PQ H3A 2T5, Canada
[4] McGill Univ, Dept Epidemiol & Biostat, Montreal, PQ H3A 2T5, Canada
[5] Univ British Columbia, Dept Med, Vancouver, BC V5Z 1M9, Canada
[6] McMaster Univ, Hamilton, ON L8S 4L8, Canada
[7] Univ Western Ontario, London, ON N6A 3K7, Canada
关键词
D O I
10.1001/archinte.167.3.265
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The validated Blatchford risk score (BRS) predicts outcomes in patients with nonvariceal upper gastrointestinal tract bleeding, before endoscopy; completion of the Rockall score requires endoscopy. The aims of this study were to predict whether the modified BRS (mBRS) can predict (1) endoscopic high-risk stigmata (HRS) and (2) rebleeding and mortality. Methods: Clinical and demographic characteristics on 1869 patients from 6 Canadian provinces were prospectively entered into the Registry for Upper GI Bleeding and Endoscopy database, recording 30-day rebleeding and mortality. The Rockall score and mBRS (hemoglobin level, hemodynamic instability, and presence of melena, liver disease, or cardiac failure; urea and syncope were not recorded) were calculated. Logistic regression was used to assess the association between an mBRS of 1 or less with HRS and with rebleeding and mortality. Results: The mean (SD) age of the patients was 66 (17) years, with 62% men and a mean of 2.5 comorbidities. Of the 1860 patients with 30- day rebleeding data, 334 (18.0%) rebled; 5.3% died. The mBRS was 0 in 3% and 1 or less in 9.8% of patients; HRS were seen in 31.0% of patients. An mBRS of 1 or less was associated with lower rebleeding (5% vs 19%; P <. 001) and mortality (0.5% vs 5.8%; P=. 003), and was significant in multivariate analysis for rebleeding (odds ratio, 0.24; 95% confidence interval, 0.12-0.48) and mortality (odds ratio, 0.12; 95% confidence interval, 0.02-0.90). The HRS were less frequent when the mBRS was 1 or less (16.9% vs 32.7%; odds ratio, 0.4;95% confidence interval, 0.3-0.6). Patients with a low mBRS with HRS had a low rebleeding rate (3.3%) and a lower apparent benefit from endoscopic therapy. Conclusions: An mBRS of 1 or less identifies approximately 10% of patients with gastrointestinal tract bleeding with a low likelihood of having HRS and a low risk of adverse outcomes. A prospective randomized study is required to examine whether this subgroup of patients presenting after hours could be discharged safely from emergency departments with arrangements for (urgent) outpatient endoscopy.
引用
收藏
页码:265 / 270
页数:6
相关论文
共 23 条
[1]   Nasogastric aspirate predicts high-risk endoscopic lesions in patients with acute upper-GI bleeding [J].
Aljebreen, AM ;
Fallone, CA ;
Barkun, AN .
GASTROINTESTINAL ENDOSCOPY, 2004, 59 (02) :172-178
[2]  
Almela P, 2001, AM J GASTROENTEROL, V96, P2341
[3]   Intravenous proton pump inhibitors before endoscopy in bleeding peptic ulcer with high-risk stigmata: A multicentre comparative study [J].
Andrews, CN ;
Levy, A ;
Fishman, M ;
Hahn, M ;
Atkinson, K ;
Kwan, P ;
Enns, R .
CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2005, 19 (11) :667-671
[4]   Meta-analysis: proton-pump inhibition in high-risk patients with acute peptic ulcer bleeding [J].
Bardou, M ;
Toubouti, Y ;
Benhaberou-Brun, D ;
Rahme, E ;
Barkun, AN .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2005, 21 (06) :677-686
[5]   Consensus recommendations for managing patients with nonvariceal upper gastrointestinal bleeding [J].
Barkun, A ;
Bardou, M ;
Marshall, JK .
ANNALS OF INTERNAL MEDICINE, 2003, 139 (10) :843-857
[6]   The Canadian Registry on nonvariceal Upper Gastrointestinal Bleeding and Endoscopy (RUGBE): Endoscopic hemostasis and proton pump inhibition are associated with improved outcomes in a real-life setting [J].
Barkun, A ;
Sabbah, S ;
Enns, R ;
Armstrong, D ;
Gregor, J ;
Fedorak, RN ;
Rahme, E ;
Toubouti, Y ;
Martel, M ;
Chiba, N ;
Fallone, CA .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2004, 99 (07) :1238-1246
[7]   A sampling of Canadian practices in managing nonvariceal upper gastrointestinal bleeding before recent guideline publication: Is there room for improvement? [J].
Bensoussan, K ;
Fallone, CA ;
Barkun, AN ;
Martel, M .
CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2005, 19 (08) :487-495
[8]   A risk score to predict need for treatment for upper-gastrointestinal haemorrhage [J].
Blatchford, O ;
Murray, WR ;
Blatchford, M .
LANCET, 2000, 356 (9238) :1318-1321
[9]   Addition of a second endoscopic treatment following epinephrine injection improves outcome in high-risk bleeding ulcers [J].
Calvet, X ;
Vergara, M ;
Brullet, E ;
Gisbert, JP ;
Campo, R .
GASTROENTEROLOGY, 2004, 126 (02) :441-450
[10]   Outpatient management for low-risk nonvariceal upper GI bleeding: a randomized controlled trial [J].
Cipolletta, L ;
Bianco, MA ;
Rotondano, G ;
Marmo, R ;
Piscopo, R .
GASTROINTESTINAL ENDOSCOPY, 2002, 55 (01) :1-5